{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:56:20Z","timestamp":1761663380232,"version":"3.37.3"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,2]]},"abstract":"Objectives<\/jats:title>HIV<\/jats:styled-content> treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy\u2010experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long\u2010term adverse events (AEs<\/jats:styled-content>). This open\u2010label, multicentre, noninferiority study enrolled HIV<\/jats:styled-content>\u20101\u2010infected, treatment\u2010experienced adults with confirmed HIV<\/jats:styled-content>\u20101 RNA<\/jats:styled-content>\u2009\u2264\u200975 HIV<\/jats:styled-content>\u20101 RNA<\/jats:styled-content> copies\/mL currently receiving tenofovir\/emtricitabine\u2009+\u2009atazanavir\/ritonavir (TDF<\/jats:styled-content>\/FTC<\/jats:styled-content>\u2009+\u2009ATV<\/jats:styled-content>\/r) for \u2265\u20096 months with no reported history of virological failure.<\/jats:p><\/jats:sec>Methods<\/jats:title>Participants were randomized 1:2 to continue current treatment or switch to abacavir\/lamivudine + atazanavir (ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content>). Endpoints included the proportion of participants with HIV<\/jats:styled-content>\u20101 RNA<\/jats:styled-content>\u2009<\u200950 copies\/mL by time to loss of virological response (TLOVR<\/jats:styled-content>), AEs<\/jats:styled-content>, fasting lipids, and inflammatory, coagulation, bone and renal biomarkers.<\/jats:p><\/jats:sec>Results<\/jats:title>After 48 weeks, 76% (152 of 199) of ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content>\u2010treated and 79% (77 of 97) of TDF<\/jats:styled-content>\/FTC<\/jats:styled-content>\u2009+\u2009ATV<\/jats:styled-content>\/r\u2010treated participants had HIV<\/jats:styled-content>\u20101 RNA<\/jats:styled-content>\u2009<\u200950 copies\/mL (TLOVR<\/jats:styled-content>; P<\/jats:italic>\u2009=\u20090.564). Other efficacy analyses yielded similar results. Rates of new grade 2\u20134 AEs<\/jats:styled-content> were 45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment\u2010emergent grade 3\u20134 laboratory abnormalities higher with TDF<\/jats:styled-content>\/FTC<\/jats:styled-content>\u2009+\u2009ATV<\/jats:styled-content>\/r (36%) compared with ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content> (19%). Most fasting lipid levels remained stable over time; high\u2010density lipoprotein (HDL<\/jats:styled-content>) cholesterol increased modestly in ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content>\u2010treated participants. Bone and renal biomarkers improved significantly between baseline and week 48 in participants taking ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content> and were stable in participants taking TDF<\/jats:styled-content>\/FTC<\/jats:styled-content>\u2009+\u2009ATV<\/jats:styled-content>\/r. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The ABC<\/jats:styled-content>\/3TC\u2009+\u2009ATV<\/jats:styled-content> treatment\u2010switch group had similar viral suppression rates up to 48 weeks to the TDF<\/jats:styled-content>\/FTC<\/jats:styled-content>\u2009+\u2009ATV<\/jats:styled-content>\/r comparator group, with lower rates of moderate\u2010 to high\u2010grade hyperbilirubinaemia and improvements in bone and renal biomarkers.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12281","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T21:57:35Z","timestamp":1436911055000},"page":"106-117","source":"Crossref","is-referenced-by-count":18,"title":["The ASSURE<\/scp> study: HIV<\/scp>\u20101 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir\/lamivudine\u2009+\u2009atazanavir"],"prefix":"10.1111","volume":"17","author":[{"given":"DA","family":"Wohl","sequence":"first","affiliation":[{"name":"AIDS Clinical Trials Unit University of North Carolina Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bhatti","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation Beverly Hills CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CB","family":"Small","sequence":"additional","affiliation":[{"name":"New York Medical College Valhalla NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Edelstein","sequence":"additional","affiliation":[{"name":"Alameda County Medical Center Oakland CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HH","family":"Zhao","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DA","family":"Margolis","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"DeJesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center Orlando FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WG","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Kaiser Foundation Health Plan of Georgia, Inc. Atlanta GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LL","family":"Ross","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MS","family":"Shaefer","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1001\/jama.2014.8722"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1310\/hct1103-170"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.1086\/517497"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.3851\/IMP1666"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1093\/jac\/dkr316"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1310\/hct1003-129"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1097\/QAI.0b013e3181a5701c"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1093\/jac\/dkm413"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1097\/QAD.0b013e32833bee1b"},{"unstructured":"Norvir\u2002(ritonavir).Package insert2013. AbbVie Inc. North Chicago IL USA.","key":"e_1_2_8_11_1"},{"unstructured":"Reyataz\u2002(atazanavir).Package insert2013. Bristol\u2010Meyers Squibb Princeton NJ USA.","key":"e_1_2_8_12_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1002\/phar.1205"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1371\/journal.pone.0049289"},{"unstructured":"LandovitzRL RibaudoHJ OfotokunIet\u2009al.Efficacy and tolerability of atazanavir raltegravir or darunavir with FTC\/tenofovir: ACTG 5257. Abstract 85.Conference on Retroviruses and Opportunistic Infections. Boston MA USA 2014.","key":"e_1_2_8_15_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_16_1","DOI":"10.1371\/journal.pone.0096187"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_8_20_1","first-page":"6","article-title":"Update of the drug resistance mutations in HIV\u20101: March 2013","volume":"21","author":"Johnson VA","year":"2013","journal-title":"Top Antivir Med"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.1097\/QAI.0b013e3181adce44"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.1001\/jama.292.2.191"},{"doi-asserted-by":"publisher","key":"e_1_2_8_23_1","DOI":"10.1093\/infdis\/jir188"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.1086\/656417"},{"doi-asserted-by":"publisher","key":"e_1_2_8_25_1","DOI":"10.1097\/QAD.0b013e328354f4fb"},{"doi-asserted-by":"publisher","key":"e_1_2_8_26_1","DOI":"10.3851\/IMP1874"},{"doi-asserted-by":"publisher","key":"e_1_2_8_27_1","DOI":"10.1186\/1471-2334-12-38"},{"doi-asserted-by":"publisher","key":"e_1_2_8_28_1","DOI":"10.1097\/QAI.0b013e31820cf010"},{"doi-asserted-by":"publisher","key":"e_1_2_8_29_1","DOI":"10.1371\/journal.pone.0038377"},{"doi-asserted-by":"publisher","key":"e_1_2_8_30_1","DOI":"10.1371\/journal.pone.0032445"},{"doi-asserted-by":"publisher","key":"e_1_2_8_31_1","DOI":"10.1111\/hiv.12123"},{"doi-asserted-by":"publisher","key":"e_1_2_8_32_1","DOI":"10.1177\/135965350701200812"},{"doi-asserted-by":"publisher","key":"e_1_2_8_33_1","DOI":"10.1097\/QAI.0b013e3181dd911e"},{"unstructured":"RyomL MocroftA WormSWet\u2009al.Exposure to antiretrovirals (ARVs) and the risk of renal impairment among HIV+ persons with normal baseline renal function: the D:A:D study. 19th Conference on Retroviruses and Opportunistic Infections. Seattle. WA2012; USA.","key":"e_1_2_8_34_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_35_1","DOI":"10.1097\/QAD.0b013e32832cbcc2"},{"doi-asserted-by":"publisher","key":"e_1_2_8_36_1","DOI":"10.1186\/1742-6405-7-9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_37_1","DOI":"10.1097\/QAD.0b013e32833f147f"},{"doi-asserted-by":"publisher","key":"e_1_2_8_38_1","DOI":"10.1097\/QAD.0b013e32833562c5"},{"doi-asserted-by":"publisher","key":"e_1_2_8_39_1","DOI":"10.3851\/IMP2020"},{"doi-asserted-by":"publisher","key":"e_1_2_8_40_1","DOI":"10.1089\/aid.2012.0278"},{"doi-asserted-by":"publisher","key":"e_1_2_8_41_1","DOI":"10.1093\/cid\/cis1203"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:28:26Z","timestamp":1696289306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/hiv.12281"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12281","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}